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Abstract 
Background 
There is limited information on acute heart failure (AHF) and the treatment thereof in 
sub-Saharan Africa. Therefore, the aim of this study was to describe the clinical 
characteristics, causes, adherence to heart failure (HF) treatment guidelines and 
mortality of patients presenting to Groote Schuur Hospital with acute heart failure 
(AHF). 
Methods 
This is a sub-study of The Sub-Saharan Africa Survey of Heart Failure (THESUS-
HF). This sub-study is a prospective and observational survey that focused on the 
enrolment and follow-up of additional patients with AHF presenting to Groote Schuur 
Hospital entered into the existing registry, following the publication of the primary 
paper of THESUS-HF in 2012. The patients were classified into prevalent (or existing) 
or incident (or new) cases of heart failure. 
Results 
Of the 119 patients included, 69 (58%) were female and the mean (SD) age was 49.9 
(16.3) years. Prevalent cases were mostly of mixed ancestry (63.3%) with more 
hypertension (70%), diabetes mellitus (36.7%), hyperlipidaemia (33.3%) and 
ischaemic heart disease (36.7%) than incident cases. The main causes of heart failure 
were cardiomyopathy (20.2%), ischaemic heart disease (IHD) (19.3%) and rheumatic 
valvular heart disease (RHD) (18.5%). Most patients received renin-angiotensin 
system blockers and loop diuretics on discharge. There was a low rate of β-blocker, 
aldosterone antagonist and digoxin use. Rehospitalisation at 180 days occurred in 
25.2%. In-hospital mortality was 8.4 % and the case fatality rate at six months was 
26.1%. 
Conclusion 
In Cape Town the main causes of AHF are cardiomyopathy, IHD and RHD. AHF 
affects a young population and is associated with a high rate of rehospitalisation and 
mortality. There is a serious under-use of β-blockers, aldosterone antagonists and 
digoxin. An emphasis on the rigorous application of treatment guidelines is needed 
in order to reduce re-admission and mortality. 
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Literature Review 
Introduction  
 
Heart failure (HF) is a worldwide phenomenon that affects millions of people yearly 
and carries a high mortality. In the US 5.8 million people are affected with HF and the 
worldwide prevalence is estimated to be >23 million people.(1,2) The past three decades 
have seen a rise in the research associated with HF. Large multicentre studies from 
USA (e.g., ADHERE) and Europe (e.g., EHFS II) have provided a greater insight into 
the aetiology, treatment and outcomes of patients with HF in the developed world.(3,4) 
Clinical trials such as SOLVD, MERIT-HF, CIBIS-II and COPERNICUS have helped 
to establish ACE-inhibitors and beta-blockers as cornerstones in the treatment of the 
disease.(5–8) 
 
Despite these advances, there are still many unanswered questions. The causes of HF 
and demographics of the patients suffering thereof are not uniformly distributed and 
great geographic variance exists. Observational studies from sub-Saharan Africa (sSA) 
show that hypertension, rheumatic heart disease (RHD) and idiopathic 
cardiomyopathies are the main causes of heart failure in a significantly younger group 
of patients when compared to those of developed countries.(9–11) Furthermore, the 
epidemiological transition due to the movement of people from rural areas to urban 
centres in search of work and education is resulting in lifestyle changes that in turn are 
contributing to an increase in cardiovascular diseases.(12–14) There is a growing body 
of knowledge on HF in sSA, however there is a paucity of data regarding the treatment 
and outcomes of patients with acute heart failure (AHF). This study aims to address 
this need though examining the treatment and outcomes of patients presenting to a 
tertiary level hospital in Cape Town, South Africa.  
 
This literature review will focus on the available body of evidence relating to HF – the 
causes, treatment and outcomes, with a special focus on sSA. A PubMed search was 
performed using the terms “acute” or “chronic heart failure”, “cardiomyopathy” 
“valvular heart disease”, “treatment of heart failure”, “outcomes of heart failure” 
“tuberculosis” and “HIV” from January 1, 1980, through November 30, 2015. The 
reference lists of the relevant articles and reviews on the subject were consulted. Only 
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studies published in English were retrieved, and articles with important insights about 
the epidemiology, aetiology, treatment and outcomes of HF in Africa and 
internationally are cited. 
 
Incidence and demographics 
 
The advancement and improvement of medical care of endemic and emerging diseases 
has allowed for an increase in the number of older people in the population. This group 
of patients has a high risk of developing HF.(15) This has lead to HF becoming a great 
public health problem in the developed world and is associated with large numbers of 
hospitalisations, high mortality and an increased burden on financial and physical 
resources.(3,15) Analysis of Framingham Study data found that the prevalence of HF 
was high, affecting about 1% of people in their 50’s and then rising with age affecting 
10% of people in their 80’s.	The annual incidence was also found to increase with age. 
In the 45 to 54 year age group, the incidence of HF was 0.2%, rising to 4.0% in men 
85 to 94 years.(16) Clinical drug trials have provided detailed information on the natural 
history of HF, however these trials studied a highly selected group of patients.(15) Until 
recently, there were no multicentre prospective epidemiological studies describing HF 
in the general population.  
 
The first of these studies, the EuroHeart Failure Survey programme (EHFS I), 
undertaken between 2000 and 2001 enrolled 11 327 patients from 115 hospitals in 24 
countries in Europe.(15) The aim of this study was to investigate whether patients with 
known or presumed heart failure were being managed in accordance with the European 
Society of Cardiology (ESC) guidelines. This study was followed up with EFHS II in 
2006 which enrolled 3 580 patients from Northern Europe (3.5%), Western Europe 
(20.4%), Central Europe (34.4%) and Mediterranean Europe (42.4%).(4) The aims of 
this study were to assess the aetiology and precipitating factors of acute heart failure 
(AHF), the patient characteristics for acute new-onset HF and acute decompensated 
chronic HF, as well as for clinical groups classified according to ESC AHF guidelines.  
 
In 2005 the Acute Decompensated Heart Failure National Registry (ADHERE) was 
published.(3) This observational study from the USA enrolled 105 388 patients from 
274 hospitals and is the largest epidemiological study to date. The Organized Program 
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to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure 
(OPTIMIZE-HF) study collected data on 48 612 patients hospitalised for HF at 259 
hospitals in the USA.(17) These large epidemiological studies have provided great 
insight into the demographics, causes, treatment and natural history of HF in the 
developed world.  
 
In the developing world, improved control of infectious and nutritional disorders along 
with epidemiological transition have increased the risk of cardiovascular 
disease.(13,18,19) Considering this increased burden of cardiovascular disease, a review 
of published data on HF in developing countries by Mendez and Cowrie in 2001 found 
no published population-based studies of HF.(14)  Information on the epidemiology of 
HF in sSA is mostly gained from hospital-based studies, showing that CVD accounts 
for 7–10% of all medical admissions to African hospitals, with heart failure 
contributing to 3–7% of these admissions.(11) 
 
Four prospective hospital-based observational studies from the sub-continent stand 
out. The first is the Heart of Soweto Study, which was published in 2008, and enrolled 
844 patients presenting with de novo HF to Chris Hani Baragwanath Hospital in 
Soweto, South Africa.(9) This was followed by the Sub-Saharan Africa Survey of Heart 
Failure (THESUS–HF) published in 2012, which is the largest multicentre study to 
date, with 1006 patients from 9 African countries.(10) More recently the Abeokuta 
Heart Failure Clinical Registry from Nigeria described 452 consecutive patients 
presenting with AHF to the only tertiary hospital in Abeokuta, while the	prospective 
Tanzania Heart Failure (TaHeF) study examined 427 patients and the predictors of 
heart failure.(20,21) 
 
These studies along with a handful of smaller retrospective analyses have added to the 
volume of knowledge regarding HF in sSA. When comparing the data from the above-
mentioned registries, certain epidemiological and demographic differences between 
USA, Europe and Africa are revealed. Firstly, the mean age of patients with HF in 
USA and Europe is between 70-73 years.(3,15,22) This contrasts greatly with sSA, where 
the patients are between the ages of 42-59 years.(9,10,20) This evidence discloses a 
younger population of patients, who are in the socio-economic prime of their lives.  
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The proportion of women affected with HF in the developed world ranges from 39-
65%.(3,4,22) In sSA, the proportion of affected women compared to men varies by 
region. Nigeria has a lower proportion of female patients than males when compared 
to South Africa and the East African countries of Kenya and Uganda.(9,10,20,23) The 
proportion of affected males compared to females of 40-60% is similar when 
comparing the developed world to sSA.(3,4,10,20) 
 
Diabetes mellitus (DM), hypertension and ischaemic heart disease (IHD) account for 
the majority of the risk factors predisposing to the development of HF in developed 
countries.(3,15,24,25) In sSA hypertension, cardiomyopathy and RHD are the main 
predisposing factors.(26) In recent years there has been an increase in the incidence of 
DM, dyslipidaemia and obesity.(27) This is thought to be most likely due to movement 
of people from rural areas to the cities in search of work, resulting in a change in diet 
and lifestyle.(13,28) Considering this transition, the incidence of IHD remains low and 
this may be partly due to under reporting and a lack of resources to further investigate 
patients presenting to health care services with invasive diagnostic tests such as 
coronary angiography.(26,29) 
 
Human immunodeficiency virus (HIV) infection affects 30 million people worldwide 
with sSA carrying the majority of the disease burden (22 million people).(30) The 2014 
WHO Global Tuberculosis report estimates that in 2013, 9 million people developed 
tuberculosis (TB). Almost one third (29%) of TB infections occurred in sSA with over 
50% of TB cases co-infected with HIV.(31) In rural South Africa HIV and TB are the 
leading causes of death in patients under the age of 65.(32) HIV/TB co-infection has 
been recognised as an important risk factor for the development of HF in sSA and this 
further contributes to the relatively young age of patients with HF.(30,33,34)  
 
Considering the differences in age, sex and risk factors for HF when comparing 
developed countries with sSA, it is interesting to note that African-Americans share 
similar characteristics with sub-Saharan Africans. Racial differences in the 
demographics, causes and outcomes of HF have been noticed in the USA. A study 
conducted at the Cook County Hospital in Chicago studied 301 black patients with 
HF.(35) Published in 1996, this study showed a younger population (56 years) with a 
high incidence of hypertension and low incidence of myocardial infarction. These 
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observations have been further confirmed by post-hoc sub-group analysis of African-
Americans compared to their Caucasian counterparts in the SOLVD, DIG, OPTIME-
CHF, RALES and OPTIMIZE-HF studies.(36–40) A possible explanation for this 
disparity may lie in the pathophysiology of HF in African-Americans underpinned by 
differences in neurohormonal responses and genomic variances.(40–42) 
 
Aetiology 
 
HF is a clinical syndrome recognised by the constellation of symptoms and signs of 
poor effort tolerance and fluid retention as a result of neurohormonal responses to 
cardiac dysfunction.(43) Its causes are varied and differ in different parts of the world.  
 
Cardiomyopathy, RHD and hypertension are considered to be the major causes of HF 
accounting for 75.5% of cases in sSA.(10,25,40,41) In developed countries IHD alone or 
in conjunction with hypertension, atrial fibrillation and DM constitute the commonest 
causes of HF, with dilated cardiomyopathy (DCM) in the minority.(3,15,24)   
 
Cardiomyopathy accounts for 30% of cases of HF in adult Africans.(26,46) DCM, 
peripartum cardiomyopathy (PPCM) and endomyocardial fibrosis (EMF) are endemic 
to sSA.(47) DCM carries a 4 year mortality of 34%.(48) In African patients the 
aetiological factors that have been studied include undiagnosed hypertension, 
autoimmune disease, iron overload, alcohol abuse, myocarditis, pregnancy and 
nutritional deficiencies.(47) Familial and genetic associations such as HLA-DR1 and 
DRw10 antigens, reported in South African patients, have furthered the understanding 
of the pathogenesis of unexplained DCM.(49–51)   
 
The THESUS-HF study showed that 7.7% of HF was due to PPCM.(26) This disorder 
of unknown cause occurs in the last month of pregnancy and the following 5 months 
postpartum.(52) African race along with gestational hypertension and multiparity are 
some of the risk factors associated with the development of PPCM.(53) Recent evidence 
also suggests a familial and genetic predisposition to its development. (51,54) When 
compared to idiopathic DCM, patients with PPCM have a better survival and a higher 
rate of spontaneous recovery.(53,55)  
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EMF is a form of restrictive cardiomyopathy caused by fibrosis in the mural 
endocardium resulting in the restriction of ventricular diastole and entrapment of the 
papillary muscles of the atrioventricular valves.(46) In Uganda it accounts for 20% of 
HF cases and is considered to be the most common form of heart disease.(56) The 
pathogenesis remains unknown. It is suggested that an interplay between the 
environment (geography, social circumstances and infective agents) and the host (diet, 
eosinophilia) may be the basis for this pathology.(46,56) The prognosis of EMF is poor 
even with medical treatment.(46) 
 
In developing countries RHD is the most common cause of acquired heart disease in 
children, adolescents and young adults.(57) A study conducted to detect RHD in 
scholars aged between 4-24 years in South Africa and Ethiopia using 
echocardiographic screening showed a prevalence of 20.2 cases per 1000 and 31 cases 
per 1000 respectively.(58) The high mortality of RHD is well illustrated by the clinical 
outcomes of South African patients included in THESUS-HF, which showed an initial 
in-hospital mortality of 17.5%, a 60-day mortality of 24.8% and a180-day mortality of 
35.4%.(57) 
 
HIV-associated cardiomyopathy is characterised by global systolic functional 
impairment with or without left ventricular dilatation.(59) The exact prevalence in 
Africa is not clear. The Heart of Soweto Study found HIV-associated cardiomyopathy 
to be the most common cause (38%) of de novo HF in patients with HIV.(33) Other 
studies have described the prevalence to range from 5-57% in people living with 
HIV.(30) The prognosis is poor without highly active antiretroviral therapy 
(HAART).(30,59) HIV and its direct effect on the myocardium along with its effect on 
the immune system are the proposed mechanisms for the pathogenesis of the 
cardiomyopathy.(60) HIV-immunosuppression-related myocarditis due to 
opportunistic infections such as TB have also been implicated.(33,34,61,62) 
 
TB pericarditis accounts for the most common type of pericardial disease 
worldwide.(63) In sSA, TB accounts for > 90% of pericardial effusions in the HIV 
infected population.(30) Furthermore, the prevalence of myopericarditis in TB 
pericarditis has been described to be 53% in a patient cohort from Cape Town.(34) 
Constriction is a common and serious complication of TB pericarditis.(63) 
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Antituberculosis therapy, pericardiocentesis and pericardiectomy are used to treat TB 
pericarditis and its complications, yet despite these interventions, the mortality 
remains high especially in patients co-infected with HIV.(63,64) 
 
Right heart failure (RHF) accounts for a very small proportion of HF in the developed 
world, amounting to only 3.2%.(4) This contrasts considerably with findings in Africa 
where in urban South Africa 28% of HF cases were due to RHF.(65) The BOLD study 
reported that South Africa has a high prevalence of chronic obstructive airways 
disease.(66) The reason for these observations is multifactorial and potentially 
represents the sequelae of urbanisation.(28,67) Exposure to pollution, dust from mining, 
smoking, and the use of solid fuel heaters, along with HIV and TB, both important risk 
factors for RHF, contribute to the increasing prevalence of airways disease and its 
complications.(30,33,65)  
 
Treatment 
 
The development of a number of international registries in the past decade have 
provided invaluable epidemiological and clinical information aiding in the 
management of HF.(68) Current guidelines for the diagnosis and management of HF 
advocate the use of ACE-inhibitors, β-blockers and mineralocorticoid antagonists for 
symptomatic and mortality benefit.(69,70) Diuretics and digoxin are used for symptom 
control while digoxin use aids in decreasing HF hospitalization.(71) Despite these 
advances, evidence from high-income countries shows sub-optimal adherence to 
medical recommendations.(72–74)  
 
Little is known regarding the treatment practices of HF in sSA. The THESUS-HF 
registry in sSA notes three important observations regarding the management of HF. 
Firstly, there was a high incidence of the use of aspirin in patients with non-ischaemic 
HF, while the use of the hydralazine hydrochloride and nitrates combination, shown 
to be effective in patients of African decent, was hardly used.(10,75) β-blockers were 
only used in 50% of patients at six months of follow-up.(10)  
 
Retrospective post-hoc analysis of the SOLVD trial suggests a lesser response to ACE-
inhibitor in African-Americans and an increase in the rate of hospitalisations.(41) V-
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HeFT I studied the effect of the vasodilator combination of isosorbide dinitrate and 
hydralazine on HF, finding that it has no clinical benefit in their Caucasian population. 
However, in the African-American group it showed a significant survival benefit, 
suggesting that nitric oxide may play a pivotal role in the pathogenesis of HF in this 
group.(76) Following this trial, V-HeFT II was designed in order to test two therapies, 
namely that of the nitrates and hydralazine combination and the ACE-inhibitor, 
enalapril. A comparison of outcomes between Caucasians and African-Americans 
once again shows a significant benefit of ACE-inhibitors over vasodilator therapy in 
the Caucasian group. In the African-American group there was no difference in benefit 
between the two therapies.(77) Conclusions from the A-HeFT study state that the 
addition of a fixed dose of isosorbide dinitrate and hydralazine to the standard therapy 
for HF is effective and increases survival in African-American patients suffering from 
advanced HF.(75) The therapeutic benefit of the nitrate and hydralazine combination in 
sub-Saharan Africans is unknown and is currently being investigated in a prospective, 
placebo-controlled, double-blinded, randomised study comparing treatment with 
hydralazine/isosorbide dinitrate versus placebo in addition to standard care in 500 
African patients admitted with acute heart failure and left ventricular dysfunction (B-
AHEF).(29) 
 
In contrast to the developed world, the high prevalence of HIV and TB and their 
cardiovascular manifestations add another dimension to the treatment of HF in sSA. 
There is a paucity of evidence regarding the treatment of HIV in patients with HF, and 
whether the early introduction of HAART in these patients changes the outcome of 
HF is unknown.(10,30) With regards to the treatment of TB pericardial disease, the IMPI 
trial examined the use of prednisolone as an adjunctive therapy to TB therapy. The 
results showed that prednisolone did not have a significant effect on the combined 
outcome of death from all causes, cardiac tamponade requiring pericardiocentesis, or 
constrictive pericarditis. However, the study did demonstrate that the use of adjunctive 
glucocorticoids reduces the incidences of pericardial constriction and hospitalisation. 
These beneficial effects are similar in both HIV-positive and HIV-negative patients. 
There was however an increase in the incidence of HIV-associated malignancies in 
immunosuppressed patients. (78)  
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Pharmacological therapy forms the cornerstones of HF treatment. However, evidence 
from the developed world shows that despite appropriate prescribing of medication, 
patient education and adherence to therapy, lifestyle and behavioural changes 
contribute significantly to re-hospitalization and long-term outcomes in HF 
patients.(79,80) This has prompted the development of HF management programs 
utilizing a multidisciplinary approach in order to educate patients and their carers 
about HF, provide support with regards to diet, risk factor modification and adherence 
to therapy, along with early recognition of decompensating HF.(79,80) The 
implementation of these strategies has aided in reducing mortality and re-
hospitalisation, improving quality of life and decreasing healthcare costs.(81,82) 
 
Information regarding medication adherence, self-care behaviour and knowledge 
about HF in Africa is scarce.(74) A study of urban Africans in Soweto, South Africa, 
showed that individual medication adherence ranged from 64-79%, behavioural 
adherence varied from 2.5-98% and that treatment knowledge was poor with half of 
the patients unable to name medication side-effects or their functions.(74)  
 
Considering the current understanding of HF in Africa, specific areas of management 
have been highlighted. These include prevention and management of risk factors 
associated with HF in the African context, improved adherence to current treatment 
recommendations, long-term treatment and follow-up of PPCM, family screening for 
cardiomyopathy in patients with unexplained DCM and increasing research into 
treatments for HF including nitrate/hydralazine combination, digoxin, bromocriptine 
and pentoxifylline.(29) 
 
Outcome 
 
HF is one of the most common causes of admission to hospital and carries with it poor 
outcomes worldwide.(3,4,83,84) The Framingham study shows that after receiving the 
diagnosis of HF, the one year and five year survival rates are 57% and 25% 
respectively for men, and 64% and 38% respectively for women.(85) The ADHERE, 
EHFS II and OPTIMIZE-HF registries showed an in-hospital mortality of 3.8-
6.7%.(3,4,17) De novo HF and patients treated in intensive care unit (ICU) had poorer 
outcomes, while hypertensive heart disease had the best outcome.(3,4) With regards to 
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outcomes, OPTIMIZE-HF reported 8.6% mortality at 90 days with a median time to 
death of 42 days.(17) The length of stay described in these registries varied from 3-14 
days, with a clear distinction between Europe and USA, at 11 days and 4.3 days 
respectively.(3,4) This may represent differing practices and access to specialist opinion	
thus affecting outcome, depending on the hospitals to which patients are admitted.(86) 
 
The limited data from sSA show similar in-hospital mortality, at 3.8% and 4.2% in the 
Nigerian AHF registry and THESUS-HF, respectively.(10,20) This similarity in 
outcomes is of interest considering the demographic and aetiological differences 
between the developed world and sSA. This suggests that once HF occurs, its 
progression is independent of the patient characteristics.(10) Despite the similar 
outcomes, the causes of HF leading to death are different with endemic causes such as 
DCM, PPCM and EMF accounting for the majority of deaths.(10) However, 
epidemiological transition with changes in diet and socio-economic context in many 
of the developing countries may see non-endemic causes of HF increase the burden of 
disease and mortality.(13,14,28,87) Length of stay in studies from sSA are longer than 
those reported in high income countries.(10,20) Sub-analysis of predictors and outcomes 
of 60-day readmission or death and 180-day mortality of the THESUS-HF study shows 
that the main predictors for adverse outcomes in sSA are similar to the rest of the 
world. Exceptions to this include the effect of HIV status on mortality and the lack of 
prediction by sodium on readmission and deaths.(88) 
 
Conclusion 
 
The increasing prevalence of HF in the developed world is setting great health and 
social challenges.(15,18,89) In USA alone, it is estimated that $12.7 billion per annum is 
spent on the in-patient management of HF.(89) The development of large multicentre 
registries in the USA and Europe has provided great insight into the aetiology, 
treatment, and outcome of HF.(3,15,73) Furthermore, the development of strategies 
aimed at prevention, improved adherence to treatment and long-term monitoring of 
HF show promising results.(80–82) 
 
In Africa, improvements in the control of communicable diseases and malnutrition 
along with population migration to urban centres underpins the increase of 
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cardiovascular disease, which is becoming a significant cause of morbidity and 
mortality.(90) In 2008 communicable, maternal, perinatal and nutritional conditions 
accounted for the majority of deaths in South Africa. However, cardiovascular disease 
was the main cause of death amongst non-communicable diseases.(12) There is still a 
lack of information on HF in Africa and in order to tackle this increasing public health 
problem, further epidemiological, etiological and treatment information is needed in 
order to develop health policies for the diagnosis, management, prevention and control 
of HF.(14,18,47,91) Finally, given the contemporary understanding of HF in sSA, certain 
areas of research have been suggested, including clinical trials on fixed-dose 
isosorbide dinitrate/hydralazine combination and bromocriptine, the study of coronary 
artery disease as a cause of HF and examining the use of molecular genetic testing in 
the diagnosis and management of cardiomyopathies.(29) 
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Abstract 
Background 
There is limited information on acute heart failure (AHF) and the treatment thereof in 
sub-Saharan Africa. Therefore, the aim of this study was to describe the clinical 
characteristics, causes, adherence to heart failure (HF) treatment guidelines and 
mortality of patients presenting to Groote Schuur Hospital with acute heart failure 
(AHF). 
Methods 
This is a sub-study of The Sub-Saharan Africa Survey of Heart Failure (THESUS-
HF). This sub-study is a prospective and observational survey that focused on the 
enrolment and follow-up of additional patients with AHF presenting to Groote Schuur 
Hospital entered into the existing registry, following the publication of the primary 
paper of THESUS-HF in 2012. The patients were classified into prevalent (or existing) 
or incident (or new) cases of heart failure. 
Results 
Of the 119 patients included, 69 (58%) were female and the mean (SD) age was 49.9 
(16.3) years. Prevalent cases were mostly of mixed ancestry (63.3%) with more 
hypertension (70%), diabetes mellitus (36.7%), hyperlipidaemia (33.3%) and 
ischaemic heart disease (36.7%) than incident cases. The main causes of heart failure 
were cardiomyopathy (20.2%), ischaemic heart disease (IHD) (19.3%) and rheumatic 
valvular heart disease (RHD) (18.5%). Most patients received renin-angiotensin 
system blockers and loop diuretics on discharge. There was a low rate of β-blocker, 
aldosterone antagonist and digoxin use. Rehospitalisation at 180 days occurred in 
25.2%. In-hospital mortality was 8.4 % and the case fatality rate at six months was 
26.1%. 
Conclusion 
In Cape Town the main causes of AHF are cardiomyopathy, IHD and RHD. AHF 
affects a young population and is associated with a high rate of rehospitalisation and 
mortality. There is a serious under-use of β-blockers, aldosterone antagonists and 
digoxin. An emphasis on the rigorous application of treatment guidelines is needed 
in order to reduce re-admission and mortality. 
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Introduction 
Heart failure (HF) is a worldwide phenomenon that affects millions of people yearly 
and carries a high mortality. In the US, 5.8 million people are affected by HF and 
worldwide >23 million people are thought to be affected.[1,2] The past three decades 
have seen a rise in the research on HF. Large multicentre studies from USA (e.g., 
ADHERE) and Europe (e.g., EHFS II) have provided a greater insight into the 
aetiology, treatment and outcomes of patients with HF in the developed world.[3,4]  
Observational studies from sub-Saharan Africa (sSA) show that hypertension, 
rheumatic valvular heart disease and idiopathic cardiomyopathies are the main causes 
of HF affecting a young population.[5–7] This epidemiological pattern is strikingly 
different from that of the developed world where a much older population suffer from 
HF, with ischaemic heart disease (IHD) the primary cause.[3,4] Despite these 
differences, the epidemiological transition is resulting in the rise of diabetes mellitus 
(DM), hypertension and IHD in sSA.[7,8] In 2008 communicable, maternal, perinatal 
and nutritional conditions accounted for the majority of deaths in South Africa. 
However, cardiovascular disease was the main cause of death amongst non-
communicable diseases.[9] 
There is limited information on the use of evidence-based interventions and outcome 
of HF in Africa. Contemporary epidemiological, aetiological and treatment 
information is needed in order to develop appropriate health policies for the diagnosis, 
management, prevention and control of HF in Africa. [11,12] 
This study aimed to explore the treatment practices of doctors and outcomes of patients 
with congestive or acute heart failure (AHF) at Groote Schuur Hospital, a tertiary level 
academic institution in Cape Town, South Africa that serves as a referral hospital for 
5 million people. Furthermore, the clinical features and causes of heart failure were 
explored. 
Methods 
Study design and clinical setting 
This is a sub-study of The Sub-Saharan Africa Survey of Heart Failure (THESUS-
HF), a prospective, multicentre, observational survey of patients with AHF admitted 
to 12 university hospitals in 9 countries.[6] The sub-study that is reported here is based 
on the enrolment of additional patients with AHF followed up in the existing 
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THESUS-HF registry presenting to Groote Schuur Hospital. Patients with AHF 
(incident (i.e., de novo) or prevalent (i.e., decompensation of previously diagnosed 
heart failure)) were added to the registry following the publication of the primary paper 
of THESUS-HF in 2012.  
Inclusion and exclusion criteria 
The inclusion and exclusion criteria are the same as the criteria published in the 
THESUS-HF study.[6] Briefly, patients older than 12 years with the diagnosis of AHF 
based on clinical evaluation and confirmed by echocardiography were enrolled. The 
exclusion criteria were acute ST-elevation myocardial infarction, known severe renal 
failure (patients undergoing dialysis or creatinine >350 µmol/L), nephrotic syndrome, 
hepatic failure or other causes of hypoalbuminaemia.  
Case definition and data collection 
The diagnosis of HF was based on finding the clinical syndrome of effort intolerance 
(i.e., shortness of breath, dyspnoea, and / or fatigue) associated with features of fluid 
retention (i.e., peripheral oedema, orthopnoea, paroxysmal nocturnal dyspnoea, raised 
jugular venous pressure, pulmonary oedema, and / or tender hepatomegaly) in the 
presence of clinical signs of cardiac dysfunction (i.e., low blood pressure, displaced 
apex, presence of third heart sound). The presence of cardiac dysfunction was 
confirmed by echocardiography performed by a trained echocardiographer. The cause 
of HF was based on information obtained from the history, physical examination, 
echocardiography, and special aetiological investigations interpreted by the admitting 
team on the index admission. Where no cause for HF was stated the research team 
determined the aetiology from the given data.   
For this study, consecutive patients that were enrolled into the Groote Schuur Hospital 
THESUS-HF registry from 1 June 2012 to 31 May 2014 (24 months) with more than 
90% completed data were selected. The THESUS-HF registry holds the basic clinical 
information as determined by the clinical history and previous medical records, along 
with an echocardiogram report confirming the diagnosis of HF. Furthermore, patients 
were followed up for 180 days to document their clinical outcomes of rehospitalisation 
and death. Their baseline demographic and clinical information, echocardiographic 
findings, treatment and clinical outcomes were entered onto a data capture sheet by 
the research nurse and echocardiographer. Outstanding demographic, clinical, 
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treatment and outcomes data were collected through folder review, pharmacy records 
and telephonic consultations with the study participants. All completed data capture 
sheets were entered into the THESUS-HF database. 
Statistical analysis 
Data were analysed using the Statistical Package for Social Sciences (SPSS) and 
ROOT.[12] Normally distributed continuous data are presented as the mean with 
standard deviation, and non-Gaussian distributed variables as the median plus range. 
Categorical data are presented as percentages. Case fatality rate was calculated at 
discharge and at six months of follow-up. 
Ethics 
The University of Cape Town Human Research Ethics Committee granted ethics 
approval for this study (Ethics number: REC REF: 579/2014). All patients entered into 
the THESUS-HF registry gave written informed consent.  
Results 
Baseline patient characteristics on admission 
One hundred and twenty patients were enrolled in the THESUS–HF registry at Groote 
Schuur Hospital between 1 June 2012 and 31 May 2014.  One patient was excluded 
due to missing clinical details. Table 1 shows the baseline clinical characteristics for 
the total cohort (119 patients) and compares the incident cases (first presentations) 
with the prevalent cases (recurrent presentations). The mean (SD) age of the cohort 
was 49.9 (16.3) years. Sixty-nine (58%) patients were female and the predominant 
population groups were black African (n=59 [49.6%]) and mixed ancestry (n=54 
[45.4%]).  
The prevalent cases were more likely to be people of mixed ancestry with more 
hypertension, DM, hyperlipidaemia, IHD, pericardial disease, cardiomyopathy and a 
higher New York Heart Association (NYHA) functional class than incident cases. 
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Table 1. Baseline Clinical Characteristics of 119 Patients with Acute Heart Failure at Groote Schuur 
Hospital 
Characteristics All cases (N=119) 
Incident cases 
(N=89) 
Prevalent cases 
(N=30) P value 
Age, y     
  Mean (SD) 49.9 (16.3) 48.6 (16.2) 53.7 (16.4) .143 
Sex, No. (%)    .349 
  Female 69 (58.0) 53 (59.6) 16 (53.3)  
  Male 50 (42.0) 36 (40.4) 14 (46.7)  
Race, No. (%)    .005 
  African 59 (49.6) 51 (57.3) 8 (26.7)  
  Caucasian 4 (3.4) 3 (3.4) 1 (3.3)  
  Mixed ancestry 54 (45.4) 35 (39.3) 19 (63.3)  
  Asian 2 (1.7) 0 (0) 2 (6.7)  
No. of AHF admissions in last 12 
months, No. (%)    
Not 
applicable 
  0 89 (74.8) 89 (100)   
  1 22 (18.5)  22 (73.3)  
  2 4 (3.4)  4 (13.3)  
  3 4 (3.4)  4 (13.3)  
Hypertension, No. (%) 58 (48.7) 37 (41.6) 21 (70.0) .006 
Diabetes mellitus, No. (%) 26 (21.8) 15 (16.9) 11 (36.7) .025 
Smoking, No. (%) 46 (38.7) 31 (34.8) 15 (50) .105 
Hyperlipidaemia, No. (%) 13 (10.9) 3 (3.4) 10 (33.3) <.001 
Ischaemic heart disease, No. (%) 17 (14.3) 6 (6.7) 11 (36.7) <.001 
Atrial fibrillation, No. (%) 6 (5.0) 5 (5.6) 1 (3.3) .526 
Stroke, No. (%) 5 (4.2) 3 (3.4) 2 (6.7) .372 
Pericardial disease, No. (%) 3 (2.5) 0 (0) 3 (10) .015 
Valvular heart disease, No (%) 12 (10.1) 10 (11.2) 2 (6.7) .374 
Cardiomyopathy, No. (%) 11 (9.2) 4 (4.5) 7 (23.3) .005 
Cor Pulmonale, No. (%) 7 (5.9) 3 (3.4) 4 (13.3) .066 
HIV, No. (%) 14 (11.8) 10 (11.2) 4 (13.3) .490 
PVD, No. (%) 2 (1.7) 2 (2.2) 0 (0) .558 
NYHA, No. (%)    <.001 
  I 23 (23.7) 23 (34.3) 0 (0)  
  II 20 (20.6) 17 (25.4) 3 (10)  
  III 44 (45.4) 24 (35.8) 20 (66.7)  
  IV 10 (10.3) 3 (4.5) 7 (23.3)  
Body mass index     
  Mean (SD) 27.4 (9.8) 27.6 (10.5) 26.7 (7.6) .680 
Systolic blood pressure, mm Hg     
  Mean (SD) 134.6 (33.2) 137.4 (32.9) 126.3 (33.3) .115 
Diastolic blood pressure, mm Hg     
  Mean (SD) 81.9 (22.5) 82.4 (23.3) 80.5 (20.1) .688 
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Heart rate, bpm     
  Mean (SD) 102.5 (22.7) 102.7 (24.3) 101.9 (17.3) .865 
Respiratory rate, BPM     
  Mean (SD) 22.8 (5.3) 23.0 (5.7) 22.0 (3.5) .370 
Oedema, No. (%)    .762 
  0 37 (31.1) 27 (30.3) 10 (33.3)  
  1+ 1 (0.8) 1 (1.1) 0 (0)  
  2+ 21 (17.6) 17 (19.1) 4 (13.3)  
  3+ 60 (50.4) 44 (49.4) 16 (53.3)  
Pulmonary oedema, No. (%)    .038 
  0 46 (38.7) 33 (37.1) 13 (43.3)  
  1 4 (3.4) 2 (2.2) 2 (6.7)  
  2 28 (23.5) 26 (29.2) 2 (6.7)  
  3 41 (34.5) 28 (31.5) 13 (43.3)  
LVEF, %     
  Mean (SD) 34.1 (16.9) 35.9 (17.4) 28.2 (14.0) .085 
Creatinine, µmol/dL     
  Mean (SD) 109.7 (75.4) 110.2 (83.9) 108.4 (43.5) .912 
Urea, mmol/L     
  Mean (SD) 10.2 (7.5) 9.7 (7.2) 11.6 (8.3) .250 
Sodium     
  Mean (SD) 136.9 (6.3) 137.0 (6.6) 136.9 (5.7) .943 
Haemoglobin, g/dL     
  Mean (SD) 12.3 (2.6) 12.1 (2.7) 12.7 (2.4) .329 
White cell count, No./µL     
  Mean (SD) 9.7 (4.5) 9.8 (4.5) 9.2 (4.5) .482 
  Abbreviations: AHF, acute heart failure; HIV, human immunodeficiency virus; LVEF, left ventricular ejection 
fraction; NYHA, New York Heart Association class; PVD, peripheral vascular disease 
Oedema: 
0: Complete absence of skin indentation with mild digital pressure in all dependent areas 
1+: Indentation of skin that resolves over 10-15 seconds 
2+: Indentation of skin is easily created with limited pressure and disappears slowly (15-30 seconds or more) 
3+: Large areas of indentation easily produced and slow to resolve (> 30 seconds) 
Pulmonary oedema: 
0: No rales heard after clearing cough 
1: Moist or dry rales heard in lower ⅓ of one or both lung fields that persist after cough 
2: Moist or dry rales heard throughout the lower half to ⅔ of one or both lungs 
3: Moist or dry rales heard throughout both lung fields 
Causes of heart failure 
The main causes of HF were cardiomyopathy (n=24 [20.2%]), IHD (n=23 [19.3%]) 
and valvular heart disease (n=22 [18.5%]). Hypertension accounted for 10.1% (n=12) 
of the cohort. Due to the small sample size, cardiomyopathy represents the cumulative 
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causes of cardiomyopathy, and includes PPCM, idiopathic DCM and HIV 
cardiomyopathy. Figure 1 shows the causes of heart failure including other causes. 
The other causes included toxins, arrhythmias, and Grave’s disease.  
 
	
Figure 1 Causes of heart failure 
 
Therapies for heart failure: Admission and discharge/day 7 admission 
Intravenous loop (IV) diuretics were the most commonly used IV therapy on 
admission (n=94 [79%]), while renin-angiotensin system blockers were the most 
commonly used oral treatment (n=70 [59.3%]).  Mechanical ventilation and 
dobutamine were used in only 0.9% (n=1) and 1.7% (n=2) of cases respectively. 
Renin-angiotensin system blockers (73.0% [n=81]), loop diuretics (74.6% [n=82]) and 
β-blockers (42.7% [n=47]) were most commonly issued on discharge. On discharge 
only 26.1% (n=15) received aldosterone antagonists and 15.5% (n=17) digoxin. IV 
dopamine, IV digoxin and oral hydralazine were never prescribed. Table 3 shows the 
IV and oral therapies used in incident and prevalent cases. 
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Table 3.  Prescribed Medication on Admission and Discharge or Day 7 Admission 
Treatment All Cases Incident Cases Prevalent Cases 
 Admission 
(No/%) 
Discharge/
D7 (No/%) 
Admission 
(No/%) 
Discharge/
D7 (No/%) 
Admission 
(No/%) 
Discharge/
D7 (No/%) 
Nitrates (IV) 4 (3.5) 0 (0.0) 3 (3.5) 0 (0.0) 1 (3.3) 0 (0.0) 
Furosemide (IV) 94 (79.0) 20 (18.0) 71 (79.8) 13 (15.9) 23 (76.7) 7 (24.1) 
Dobutamine 2 (1.7) 0 (0.0) 2 (2.4) 0 (0.0) 0 (0.0) 0 (0.0) 
Mechanical 
ventilation 1 (0.9) 0 (0.0) 0 (0.0) 0 (0.0) 1 (3.3) 0 (0.0) 
ACE 
inhibitor/ARB 70 (59.3) 81 (73.0) 48 (54.5) 57 (69.5) 22 (73.3) 24 (82.8) 
Loop diuretics 24 (20.7) 82 (74.6) 17 (19.8) 60 (74.1) 7 (23.3) 22 (75.9) 
Beta blockers 21 (18.3) 47 (42.7) 13 (15.3) 32 (39.5) 8 (26.7) 15 (51.7) 
Digoxin 15 (13.2) 17 (15.5) 9 (10.6) 12 (14.8) 6 (20.7) 5 (17.2) 
Nitrates 4 (3.5) 9 (8.2) 3 (3.5) 4 (4.9) 1 (3.3) 5 (17.2) 
Aldosterone 
antagonists 15 (12.9) 29 (26.1) 9 (10.5) 19 (23.2) 6 (20.0) 10 (34.5) 
Simvastatin 36 (30.8) 36 (32.4) 21 (24.1) 21 (25.6) 15 (50.0) 15 (51.7) 
Aspirin 30 (25.6) 32 (28.8) 19 (21.8) 19 (23.2) 11 (36.7) 13  (44.8) 
All 
anticoagulation 45 (38.5) 32 (28.8) 32 (36.8) 26 (31.7) 13 (43.3) 6 (20.7) 
Anticoagulation: warfarin, heparin, enoxaparin 
Length of stay, rehospitalisation, and case fatality rate 
The mean length of stay in hospital for all cases was 9.2 days (SD=12.2) with a median 
of 6 days (range: 1-109 days). Rehospitalisation at 180 days occurred in 25.2% (n=30) 
of the total cohort. Twelve patients (10.1%) were lost to follow-up. The reasons for 
this included no reply to telephonic calls (n=11) and one patient left for another 
province.  The rate of death during hospital admission was 8.4 % (10 of 119 patients) 
and case fatality rate at six months was 26.1% (31 of 119 patients).  
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Discussion 
The main findings of this study include a relatively young population suffering from 
HF, with prevalent cases more likely to have DM, HT, IHD and more advanced 
disease. Furthermore, cardiomyopathy, IHD and rheumatic valvular heart disease 
account for the majority of causes of HF. There is an under-use of β-blockers,   
aldosterone antagonists and digoxin. Finally, there was high rehospitalisation and 
mortality rates.    
The mean age of patients with AHF is 49.9 years and 58% are female. These findings 
are similar to what has been observed in other registries from sSA.[5,6,13,14] This is 
significant as it demonstrates that HF in Cape Town affects the bread-winner 
generation, rather than the elderly as has been noted in the developed world.[3,4] 
Secondly there is a difference in the clinical characteristics between patients with new-
onset disease and those with a previous diagnosis of HF. The patients with prevalent 
disease are mostly from the mixed ancestry community. This may be representative of 
Cape Town’s population demographics where the mixed ancestry community 
constitute the largest group in the Western Cape.[15] Furthermore those with prevalent 
disease have more hypertension, DM, hyperlipidaemia and IHD. Finally, their baseline 
NYHA functional class is higher possibly indicating a group of patients with more 
advanced HF, which may reflect sub-optimal treatment of HF along with poor follow-
up and education regarding HF.  
In sSA hypertension, RHD and the endemic cardiomyopathies account for the majority 
of HF cases.[6] In this study, cardiomyopathy, IHD and rheumatic valvular heart 
disease are the leading causes of AHF in Cape Town, accounting for 60% of cases 
referred to tertiary care. Of interest is the high prevalence of IHD. Observational 
studies from sSA state the incidence of IHD as a cause of HF to be between 0.4-
9%.[5,6,13,14] In this study 19.3% of patients were diagnosed with an ischaemic cause of 
heart failure. One of the possible reasons for the disparity in observations may be due 
to the effects of urbanisation. It has been shown in the literature that movement of 
people from rural areas to urban centres results in a change in diet and lifestyle 
predisposing to the development of IHD.[7,8] Another reason may be the availability of 
a specialist cardiology service to this study cohort, which may have allowed for better 
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diagnostic tests (angiography and echocardiography) resulting in the increased 
diagnosis of IHD. Hypertensive HF is less prevalent in this study than is described in 
other studies from sSA. The reason for this is not clear, and requires further 
investigation.  
The rate of β-blocker use was low in this study, 42.7%, when compared with EHFS II 
(61%) but similar to rates of use observed in the Tanzania Heart Failure (TaHeF) study 
(42%) and THESUS-HF (50%).[4,6,16] The low rate of β-blocker use may be due to the 
severity of HF treated. In this cohort over half of the patients presented with NYHA 
functional class of III and IV combined. On discharge 26.1% of patients received 
aldosterone antagonists and 15.5% received digoxin. This is considerably lower than 
has been described in the rest of sSA, where aldosterone and digoxin are prescribed in 
60-75% and 31-72% of cases respectively.[5,6,13,14] The side-effect profiles, potential 
drug interactions and close monitoring of these therapies in a population group where 
compliance to follow-up and access to specialist care is sub-optimal may explain their 
limited use. Hydralazine use was low possibly because of its limited availability at 
Groote Schuur Hospital, and also known low use by physicians in sub-Saharan 
Africa.[13} In this study 28.8% of patients were discharged with aspirin. This is far less 
than is described in THESUS-HF, where more than 50% of patients were discharged 
on aspirin despite the low prevalence of ischaemic HF.[6] This study shows a 
population with a high prevalence of IHD. Whether the use of aspirin in this study is 
in keeping with the prevalence of IHD as identified in this cohort, needs to be further 
evaluated.  
The mean length of stay was 9.2 days and is similar to the number of admission days 
described in studies from developed nations and sSA.[4–6,13] The six-month 
readmission rate was 25.2%. The reasons for this high re-admission rate may be three 
fold. Firstly, sub-optimal adherence to evidence based treatments may be resulting in 
high re-admission rates.  Gaps in the patients’ understanding of HF and importance of 
treatment follow up and lifestyle adherence may be a further contributory factor. And 
finally, hospital bed pressure may lead to premature discharge of HF patients. The in-
hospital and six month mortality rates were 8.4% and 26.1% respectively. This is 
higher than is described in the rest of sSA. THESUS-HF, the largest multicentre study 
on HF to date, reported an in-hospital mortality of 4.2% and a six month mortality of 
17.8%.[6] These high mortality rates may be due to the different aetiological pattern in 
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Cape Town with a significant contribution of IHD, and a lower prevalence of 
hypertension as the primary cause of AHF. There was also a low adherence to life 
saving medications such as β-blockers and aldosterone inhibitors. These observations 
stress the importance of adhering to evidence based treatment guidelines. Furthermore, 
the management of HF is complex and requires a multidisciplinary approach 
encompassing routine follow-up with patient education, optimisation of treatment and 
social support.[16]  
This study has a number of limitations. The sample size was small and may 
underrepresent the causes of HF. A second limitation was that rehospitalisation to 
other institutions may not have been documented in all cases. Furthermore, only 
admission and discharge treatment practices are described in this study. It may be that 
the use of aldosterone and β-blockers as well as other HF treatment may have increased 
during ambulatory care in the community. There is also lack of data on HF survival 
benefit drug dosages used. Finally, 10.1% of the patient cohort was lost to follow up 
which may have contributed to an under-estimate of the case fatality rate in this study.  
Conclusion  
This study provides important insights into the demographics, causes, treatment and 
outcomes of patients with AHF in Cape Town. It confirms observations noted in earlier 
sSA HF studies showing that a young adult population is affected by HF. 
Cardiomyopathy, IHD and rheumatic valvular heart disease account for 60% of cases 
AHF. However, of concern is the high prevalence of IHD in this cohort, the highest 
reported thus far in sSA. Furthermore, there is a serious under-use of β-blockers, 
aldosterone antagonists and digoxin. The high re-admission rate and six month 
mortality may be a reflection of the sub-optimal adherence to evidence based treatment 
guidelines.  There needs to be an emphasis on the rigorous application of treatment 
guidelines in order to reduce re-admission and mortality associated with AHF in Cape 
Town. 
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01112007 Informed Consent THESUS-HF Version 1 
' 
UN IVERSITY OF CAPE TOWN u Duke Clinical Research lnstitute DUICI! UNlVSRllTY M l!DICAL CllHl!R 
THE SUb-Saharan Africa .§.urvey of t!eart failure - THESUS-HF 
in collaboration with the Departments of Medicine of GF Jooste Hospital and Groote Schuur Hospital 
Telffax 0216901053 email: nschrued@pgwc.gov.za 
Department of Medicine Principal investigator: Prof BM Mayosi 
INFORMED CONSENT FORM AND STATEMENT 
Dear Mr/Mrs./Ms ........... .......... ... .... .. . 
Explanation and purpose of the research: 
You have been admitted to hospital with the diagnosis of heart failure. The information surrounding the characteristics, 
causes, treatment and short term outcome of acute heart failure in Africa is largely unknown. 
We are doing an observational study researching these aspects of acute heart failure in order to improve our knowledge 
and future care of patients with acute heart failure. 
We would like to know if you would like to participate in the study to help us improve our knowledge about the condition 
of acute heart failure. 
Procedure and duration: 
The study will entail us asking you a few questions relating to your health and symptoms, examining you and doing a 
specialized test on the heart called an echocardiogram (ECHO) and recording all this information on a special case 
report form. This echocardiogram uses sound waves to give us a picture and movie of the heart and will not be painful. 
We will repeat the examination for the first two days after admission and on the 7th day or day of discharge to review 
your progress and to record this information. Wfj would like to gather other relevant information from your file and record 
this on the case report form. 
We will not require any special blood tests or be testing any medicines at any time. We will not be taking over your 
treatment from your admitting doctor whil'! you are in hospital. 
We would like to contact you in between une (1) months and one (1) year's time via telephone to enquire about your 
progress. If you are re-admitted to hospital during this time we would like to access the information from your file relating 
to your re-admission. 
Possible risks: 
The only risk to you is the breach of confidentiality by the investigators collecting the information. However we will not be 
putting your name or contact information on the case report form and you will only be assigned a unique study patient 
number. 
Any publications of the information and study findings will not contain identifying data and only the study patient number 
will be used. The contact information and identifying details for follow up will be safeguarded by the investigators to 
reduce the risk of breach of confidentiality. 
Possible benefits: 
The benefit to you is getting a specializer/ assessment and test of your heart (ECHO). If further specialized care for your 
heart condition is required based on the 11ccepted standard of practice, you will be referred to Groote Schuur Hospital for 
further assessment and care. 
-
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subheadings. If in doubt, refer to 'uniform requirements' - www.icmje.org.
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Qualification, affiliation and contact details of ALL authors must be
provided in the manuscript and in the online submission process.
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font, and contain no unnecessary formatting (such as text in boxes, with the
exception of Tables).
ILLUSTRATIONS AND TABLES
If tables or illustrations submitted have been published elsewhere, the
author(s) should provide consent to republication obtained from the copyright
holder.
Tables may be embedded in the manuscript file or provided as
'supplementary files'. They must be numbered in Arabic numerals (1,2,3...)
and referred to consecutively in the text (e.g. 'Table 1'). Tables should be
constructed carefully and simply for intelligible data representation.
Unnecessarily complicated tables are strongly discouraged. Tables must be cell-
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solely embedded in the accompanying manuscript). TIFF and PNG formats are
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image compression. Illustrations and graphs prepared in Microsoft Powerpoint
or Excel must be accompanied by the original workbook.
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CrossRef.
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Other references (e.g. reports) should follow the same format: Author(s).
Title. Publisher place: publisher name, year; pages. Cited manuscripts that
have been accepted but not yet published can be included as references
followed by '(in press)'. Unpublished observations and personal communications
in the text must not appear in the reference list. The full name of the source
person must be provided for personal communications e.g. '...(Prof. Michael
Jones, personal communication)'.
PROOFS
A PDF proof of an article may be sent to the corresponding author before
publication to resolve remaining queries. At that stage, only typographical
changes are permitted; the corresponding author is required, having conferred
with his/her co-authors, to reply within 2 working days in order for the article to
be published in the issue for which it has been scheduled.
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